Abstract
Patients with HR+/HER2-metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2-MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician's choice in HR+/HER2-MBC. Trial registration number: NCT03901339.
Original language | English (US) |
---|---|
Pages (from-to) | 705-712 |
Number of pages | 8 |
Journal | Future Oncology |
Volume | 16 |
Issue number | 12 |
DOIs | |
State | Published - Apr 2020 |
Keywords
- HER2-negative
- HR-positive
- MBC
- SN-38
- Trop-2
- antibody-drug conjugate
- metastatic breast cancer
- sacituzumab govitecan
ASJC Scopus subject areas
- Oncology
- Cancer Research